Teleflex Incorporated · NYSE:TFX
Teleflex — Wells Fargo Healthcare Conference 2018
14 slides from Teleflex's conference presentation, Sep 12, 2018
Slide 1: Teleflex Incorporated Investor Presentation
Teleflex Incorporated (NYSE: TFX) Investor Presentation
Slide 2: Important Information
Important Information 2 Forward Looking Statements This presentation and our discussion contain forward-looking information and statements, which inherently involve risks and uncertainties that could cause actual results to differ from those projected or implied in the forward–looking statements. Th
Slide 3: Our Company
Our Company 3 Business Overview Revenue by Market1 • NYSE listed – TFX 5% 10% • Global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce procedure costs 85% • Serving healthcare providers worldwide through a combination of our dire
Slide 4: Our Segments: Vascular North America
Our Segments 4 Vascular North America Revenue by Segment1 • Our vascular access products facilitate a variety of critical care therapies, including the administration of intravenous 14% 14% medications and other therapies and the measurement of blood 7% pressure and taking of blood samples through a
Slide 5: Our Segments: Anesthesia North America
Our Segments 5 Anesthesia North America Revenue by Segment1 Our anesthesia products include airway and pain management products • Our airway management products are designed to help eliminate airway related complications and improve 14% 14% procedural efficiencies for patients in surgical, critical
Slide 6: Our Segments: Surgical North America
Our Segments 6 Surgical North America Revenue by Segment1 • Our surgical products include: • Ligation and closure products, including clips and sutures 14% 14% used in a variety of surgical procedures 8% 7% 9% • Access ports used in minimally invasive surgical 12% 11% procedures, including robotic s
Slide 7: Our Segments: Interventional North America
Our Segments 7 Interventional North America Revenue by Segment1 Our interventional product portfolio consists of products used by interventional cardiologists, interventional radiologists, vascular surgeons and vein practices 14% 14% 8% 7% • Our Vascular Solutions portfolio consists of clinically 9%
Slide 8: Our Segments: EMEA and Asia
Our Segments 8 EMEA Revenue by Segment1 • Our EMEA segment designs, manufactures and distributes medical 14% 14% devices primarily used in critical care, surgical applications and 8% 7% cardiac care 12% 9% • For the twelve months ended July 1, 2018, our EMEA segment 11% represented $594.0 million, o
Slide 9: Our Segments: OEM
Our Segments 9 OEM Revenue by Segment1 • Our OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers 14% 14% 8% 7% • Provides custom-engineered extrusions, diagnostic and interventional catheters, sheath / dilator sets and kits, sutures, 9% 12% p
Slide 10: Our Segments: All Other
Our Segments 10 All Other Revenue by Segment1 • Our All Other segment includes single-se respiratory, urology and interventional urology products, as well as our Latin American 14% 14% business. 7% 8% • Our Respiratory products are used in a variety of care settings and 9% include oxygen therapy pro
Slide 11: Our Strategy
Our Strategy 11 Position Teleflex to succeed in the healthcare environment of the future Increased utilization Increased economic pressure Capitalize on Teleflex’s scope and size Take advantage of unique Teleflex opportunities Footprint consolidation Distributor to direct conversions
Slide 12: Recent Acquisitions
Recent Acquisitions 12 Mayo Mini-Lap Truphatek Ace Medical CarTika Vascular Healthcare Technologies, Holdings Nostix, LLC US, LLC Medical, Inc. Solutions, Inc. Pty. Ltd. Inc. Limited 2013 2014 2015 2016 2017 Teleflex Medical N. Stenning Vidacare Human Medics Trintris Atsina Private Limited & Co. Neo
Slide 13: Key Investment Highlights
Key Investment Highlights 13 Diversified, global medical technology company Well-positioned to take advantage of favorable industry dynamics Leading market positions with established global brands Diversified customer and supplier base Strong cash flow generation and proven history of deleveraging a
Slide 14: Thank You
THANK YOU Veleflex: